| Description |
Breast cancer (BC) is the second most common cancer in the world and, by far, the most frequent cancer among women. It is estimated that 1.67 million new BC cases were diagnosed (25.2% of all cancers in women) and BC caused 522,000 deaths (14.7% of all cancers in women) in 2012 [GLOBOCAN 2012]. Incidence rates vary nearly four-fold across the world regions, with rates ranging from 27 per 100,000 in Middle Africa and Eastern Asia to 96 in Western Europe. By 2008, the incidence of BC in China and its magnitude became so staggering that China accounted for 12.2% of global cases and 9.6% of related deaths. BC is now the most frequently diagnosed cancer in Chinese women and is the sixth leading cause of death.The goal of this project is to obtain data on the prevalence, the prognostic significance, and the potential evolution (under the influence of standard-of-care therapies) of potentially druggable molecular targets in Chinese BC through biomarker analysis of existing clinical samples. Such data can help us not only identify existing pipeline molecules for potential development for BC, but also explore completely novel targets for future development BC therapies. |
